Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin eye drop penetration study in elective eye surgery patients
ACTRN12609000066280Phase 4Not yet recruiting
- Sponsor
- Monash IVF Group
- Start
- Apr 2009
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of caspofungin in keratomycosis, sponsored by Monash IVF Group. Primary endpoint: Penetration of caspofungin into the aqueous humour of the eye. Planned start Apr 2009; status: not yet recruiting.
02
Drugs
caspofungin
03
Conditions
keratomycosis
Beyond the preview
Go deeper on ACTRN12609000066280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000066280.